Anika Therapeutics, Inc. (ANIK): M&A transaction — Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management

Anika Therapeutics, Inc.

Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).
Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.
Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.
Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.
Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Anika Therapeutics, Inc. completed a disposition involving Medacta Americas Manufacturing, Inc. for $4,500,000 in cash (closed 2025-03-07).

Action: disposition
Counterparty: Medacta Americas Manufacturing, Inc.
Consideration: $4,500,000 in cash
Closing: 2025-03-07

Exact text from the filing

Agreement”), by and among the Company, Parcus and Buyer (the “Transaction”). As consideration for the Transaction, at closing, the Buyer delivered to the Company a payment of $4,500,000 in cash. Pursuant to the Purchase Agreement, the aggregate consideration is subject to customary post-closing adjustments. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 exh_991.htm

View on SEC.gov

Browse all m&a transactions →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-001388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.